Wetherby-based life sciences company Avacta Therapeutics has announced a collaboration with tech company Tempus AI to use artificial intelligence to enhance its development of drugs…

Wetherby-based life sciences company Avacta Group has appointed Michelle Morrow as Chief Scientific Officer with effect from 4 November. Morrow brings nearly 20 years’ experience…

Wetherby-based life sciences company Avacta Group said it will present new preclinical data on two breakthroughs in its cancer drug treatment platform at the 2024…

Wetherby-based life sciences company Avacta Group said it would divest its diagnostics division and is looking at a dual listing on NASDAQ to maximize value…

Wetherby-based life sciences company Avacta Group announced that Christina Coughlin has been appointed as its new CEO, effective May 1, 2024, and that after 19 years as CEO, Alastair…

Shares of Wetherby-based life sciences company Avacta Group fell more than 25% after it carried out a heavily discounted share placing. The company said it successfully…

Wetherby-based life sciences company Avacta Group announced the appointment of experienced dealmaker Simon Bennett as chief business officer of its Therapeutics Division.  “Simon has over 26…

Wetherby-based life sciences company Avacta Group announced it has acquired Belgium-based Coris Bioconcept SRL for an upfront cash consideration of £7.4 million with an earnout…

Wetherby-based life sciences company Avacta Group said its reported group revenues for the year ended December 31, 2022, increased to £9.65 million compared from £2.94…

Shares of Wetherby-based life sciences company Avacta Group rose about 13% after it announced that its tumour targeted therapy AVA6000 “continues to show a very favourable…

Wetherby-based clinical stage oncology drug company Avacta Group said it agreed to acquire Kent-based Launch Diagnostics Holdings Ltd. for up to £37 million and that it…

Wetherby-based clinical stage oncology drug company Avacta Group plc announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the…

Wetherby-based clinical stage oncology drug company Avacta Group plc announced that AffyXell, its joint venture with Daewoong Pharmaceuticals has successfully completed a funding round to advance…

Shares of Wetherby-based clinical stage oncology drug company Avacta Group plc rose 11% on Wednesday after it announced that the first-in-human Phase I trial of…

Shares of Wetherby-based diagnostics company Avacta Group plc rose 12% on Friday after it announced that AffyXell Therapeutic, a joint venture between Avacta and Daewoong Pharmaceutical, entered into…

Wetherby-based diagnostics company Avacta Group plc announced that Vimian Group AB has acquired Avacta’s veterinary division Avacta Animal Health for up to £2.3 million. “Avacta Animal Health…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 12% on Thursday after it reported that “the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 14% on Tuesday after it announced its next pre|CISION drug candidate, AVA3996, has been selected for…

Shares of Wetherby-based diagnostics company Avacta Group plc fell about 30% on Monday after it announced it has paused sales of its Covid-19 AffiDX antigen lateral flow…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 17% on Wednesday after it said its AffiDX SARS-CoV-2 antigen lateral flow test has received a…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 4% on Monday after it announced US Food and Drug Administration (FDA) approval for its Investigational New…

Shares of Wetherby-based diagnostics company Avacta Group plc fell about 9% on Tuesday after it said it has suspended further sales of its AffiDX SARS-CoV-2 Lateral…

Shares of Wetherby-based cancer therapies and diagnostics company Avacta Group plc rose about 5% after it announced that a pre-clinical development milestone has been achieved in its…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 5% on Tuesday after it announced that a study has shown that its AffiDX antigen lateral…

Shares of Wetherby-based diagnostics company Avacta Group plc fell about 12% on Monday despite the firm announcing it entered into a non-exclusive distribution agreement with Calibre…

Shares of Wetherby-based diagnostics company Avacta Group plc rose another 18% on Friday after it announce that it has received notice of registration of its AffiDX…

Shares of Wetherby-based cancer therapies and diagnostics company Avacta Group plc rose another 8% on Tuesday after it announced positive data from the clinical validation…

Shares of Wetherby-based cancer therapies and diagnostics company Avacta Group plc rose another 8% on Tuesday after it announced it entered into a global distribution agreement…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 9% on Monday after it announced its AffiDX SARS-CoV-2 rapid antigen lateral flow test “detects the…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 18% on Tuesday after the firm said it has received the first data for its…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose about 7% on Monday after it said it entered into a commercial partnership with Mologic Ltd “to…

Wetherby-based biotherapeutics company Avacta Group plc said on Monday that AffyXell Therapeutics, its joint venture with Daewoong Pharmaceutical, has closed a Series A venture capital investment…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose 3% on Thursday after it said it has entered into a license agreement with Point Biopharma…

Wetherby-based biotherapeutics company Avacta Group plc announced on Monday “significant progress” in the development of a “highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose 12% on Thursday after the company published an update on its collaboration with the University of Glasgow…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 8% on Thursday after it said it raised £48 million by selling new shares in the…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 30% on Friday after it published a stock market statement on a “very exciting development” in…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 14% on Friday after it announced it entered a collaboration with Massachusetts-based Adeptrix to develop…